NICE TA740 Apalutamide plus androgen deprivation therapy (ADT) is recommended, within its marketing authorisation, |
as an option for treating hormone - relapsed non‑metastatic prostate cancer that is at high risk |
of metastasising in adults. High risk is defined as a blood prostate-specific antigen (PSA) level that has |
doubled in 10 months or less on continuous ADT. It is recommended only if the company provides apalutamide |
according to the commercial arrangement. |
|
NICE TA741 Apalutamide plus androgen deprivation therapy (ADT) is recommended as an option for treating |
hormone-sensitive metastatic prostate cancer in adults, only if: |
> docetaxel is not suitable |
> the company provides apalutamide according to the commercial arrangement. |
|
Gonadotrophin-releasing hormone antagonists |
Degarelix is a gonadotrphin-releasing hormone antagonist used to treat advanced hormone dependent prostate cancer which |
doesnot induce a testosterone surge or tumour 'flare'. Anti-androgen therapy is not required when Degarelix is used. |
CAMET recommends its use ONLY where LHRH analogues or concomittant anti-androgens are contra-indicated. |
|
Degarelix is recommended as an option for treating advanced hormone-dependent prostate cancer in people with spinal |
metastases NICE TA404 |
AMBER Degarelix injection with diluent 80mg and 120mg Click here to access a Prescribing Information Sheet for Degarelix (Firmagon®) |
Degarelix for the treatment of adult male patients with advanced hormone dependent prostate cancer - patients without spinal metastases |
To be recommended/initiated by specialist services. |
|
Degarelix is recommended as an alternative to lutenising hormone releasing hormone agonists (LHRH) for treatment of adult male patients with advanced hormone-dependent prostate cancer without spinal metastases ONLY in the following circumstances: |
> where LHRH analogues or concomitant anti-androgens are contra-indicated. |
> in patients on androgen deprivation therapy who have a significant cardiac history/severe cardiac disease. |
> very significant, symptomatic metastatic disease, and locally advanced disease to shrink the metastases. |
> impending bladder outlet obstruction due to prostate cancer. |
|
Degarelix Position Statement click here |
AMBER Degarelix powder and solvent for solution for injection vials )Firmagon) |
|
AMBER Relugolix–estradiol–norethisterone acetate [Ryeqo] |
NICE TA832 Recommended, within its marketing authorisation, as an option for treating moderate to severe symptoms of uterine |
fibroids in adults of reproductive age. ICB Commissioned |
|
|
|
|